Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunocabo: Cabozantinib after immune checkpoint inhibitors in hepatocellular carcinoma
2019-002860-29Phase 2Active
- Sponsor
- Humanitas Research Hospital
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Humanitas Research Hospital. Primary endpoint: Progression-free survival on cabozantinib treatment. Started May 2021; status: active.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-002860-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002860-29.